Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Doxylamine is a first-generation antihistamine used primarily as a short-term treatment for insomnia and to relieve symptoms of allergies such as sneezing, runny nose, watery eyes, and itching. It is also used in combination with other medications to treat symptoms of the common cold and in some formulations for nausea and vomiting during pregnancy. Doxylamine works by competitively inhibiting histamine at Histamine H1 receptor (histamine H1 antagonist), resulting in its sedative and anticholinergic effects. It is classified as a small molecule pharmaceutical drug[1][2][3][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on doxylamine.